A 31-year-old man with schizophrenia has been stable on risperidone 4mg daily for 18 months. He attends routine follow-up with his care coordinator. Physical examination reveals bilateral breast enlargement with milky discharge from both nipples. His prolactin level is 2800 mIU/L (normal range 86-324). He is otherwise well and his mental state remains stable. What is the most appropriate next step in management?
Q72
A 37-year-old man with bipolar affective disorder type I presents for preconception counselling with his partner. He has been stable on lithium carbonate 1200mg daily for 3 years with no relapses. He is concerned about the risks to the baby. His partner is not yet pregnant. What is the most appropriate advice regarding his lithium treatment in the context of preconception planning?
Q73
A 28-year-old woman presents with a 3-month history of believing that her thoughts are being broadcast on television and that the government is controlling her actions through radio waves. She hears multiple voices commenting on her actions. She has become increasingly socially withdrawn. She has no previous psychiatric history, no substance misuse, and no medical comorbidities. What is the most appropriate first-line pharmacological treatment?
Q74
A 52-year-old woman with a 20-year history of bipolar affective disorder has been stable on lithium carbonate 1000mg daily for 15 years. She develops hypertension and her GP starts her on ramipril 2.5mg daily. Three weeks later, she presents feeling generally unwell. Examination shows mild tremor. Blood tests show: lithium 1.7 mmol/L (previous levels 0.7-0.9 mmol/L), creatinine 95 μmol/L (baseline 88), sodium 138 mmol/L. What is the mechanism for the change in lithium level?
Q75
A 44-year-old man with chronic schizophrenia on clozapine 550mg daily presents to A&E with 12-hour history of fever (39.2°C), muscle rigidity, and confusion. His heart rate is 125 bpm, BP 160/95 mmHg. He is sweating profusely. Blood tests show: WCC 16 × 10⁹/L (neutrophils 14), CK 8500 U/L, creatinine 145 μmol/L (baseline 80). He last took clozapine 18 hours ago. What is the most likely diagnosis?
Q76
A 35-year-old man with schizophrenia stabilised on risperidone 6mg daily for 2 years presents with reduced libido and erectile dysfunction. Examination reveals bilateral gynaecomastia. Blood tests show: prolactin 1850 mU/L (normal <400), testosterone 8.2 nmol/L (normal 10-30), TSH 2.1 mU/L, free T4 14 pmol/L. Pituitary MRI shows no structural abnormality. He is distressed and considering stopping medication. What is the most appropriate management?
Q77
A 26-year-old woman with bipolar affective disorder type I presents to the emergency department with a 2-day history of confusion, tremor, and vomiting. She has been taking lithium carbonate 800mg daily. On examination, she is drowsy with a GCS of 13, temperature 37.8°C, pulse 110 bpm regular, BP 105/70 mmHg. She has coarse tremor and hyperreflexia. Blood tests show: lithium 2.8 mmol/L, sodium 148 mmol/L, potassium 4.2 mmol/L, creatinine 185 μmol/L (baseline 70), eGFR 28 ml/min/1.73m². What is the most appropriate immediate management?
Q78
A 41-year-old man with a 12-year history of paranoid schizophrenia has persistent auditory hallucinations despite trials of risperidone, olanzapine, and amisulpride at therapeutic doses for adequate durations. He is commenced on clozapine. After titration, he has been on clozapine 400mg daily for 8 weeks. His clozapine level is 380 ng/mL (therapeutic range 350-600 ng/mL) and norclozapine level is 190 ng/mL. He reports minimal improvement in hallucinations. What is the most appropriate next management step?
Q79
A 38-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward with acute mania. She is agitated, hyperactive, and has had no sleep for 4 days. She is already taking sodium valproate 1500mg daily. Her valproate level is therapeutic at 85 mg/L. She has no known allergies. Physical examination is unremarkable except for agitation. What is the most appropriate additional pharmacological treatment?
Q80
A 29-year-old man with paranoid schizophrenia has been taking olanzapine 20mg daily for 18 months with good symptom control. He attends for routine monitoring. His weight has increased from 78kg to 96kg (BMI from 24 to 29.5 kg/m²). Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L. He is concerned about the weight gain. What is the most appropriate management?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 71: A 31-year-old man with schizophrenia has been stable on risperidone 4mg daily for 18 months. He attends routine follow-up with his care coordinator. Physical examination reveals bilateral breast enlargement with milky discharge from both nipples. His prolactin level is 2800 mIU/L (normal range 86-324). He is otherwise well and his mental state remains stable. What is the most appropriate next step in management?
A. Continue current medication and monitor prolactin levels 3-monthly
B. Add cabergoline to current antipsychotic regimen
C. Switch to aripiprazole and monitor mental state closely (Correct Answer)
D. Reduce risperidone dose to 2mg daily
E. Switch to quetiapine and monitor mental state closely
Explanation: ***Switch to aripiprazole and monitor mental state closely***
- **Aripiprazole** is a **partial dopamine agonist** which effectively reduces prolactin levels by providing enough dopamine activity to inhibit the pituitary gland without blocking dopamine receptors extensively in the mesolimbic pathway.
- It is the treatment of choice for **antipsychotic-induced hyperprolactinaemia** when switching is feasible, as it balances efficacy in managing psychosis with a low risk of hormonal side effects.
*Continue current medication and monitor prolactin levels 3-monthly*
- Symptomatic **hyperprolactinaemia**, evidenced by galactorrhoea and gynaecomastia, requires intervention to prevent long-term complications such as **osteoporosis**, sexual dysfunction, and infertility.
- Simply monitoring is inappropriate when the patient is already experiencing **distressing physical symptoms** and significantly elevated prolactin levels.
*Add cabergoline to current antipsychotic regimen*
- **Dopamine agonists** like cabergoline can potentially **exacerbate or precipitate psychosis** by stimulating dopamine receptors in the mesolimbic pathway, which is counterproductive in schizophrenia.
- They are generally reserved as a last resort for hyperprolactinaemia when antipsychotic switching or dose reduction has failed or is clinically impossible due to high relapse risk.
*Reduce risperidone dose to 2mg daily*
- While a dose reduction may lower prolactin, it is often insufficient to resolve **symptomatic galactorrhoea** and significantly increases the **risk of relapse** in a patient with stable schizophrenia.
- This patient is on a therapeutic dose of 4mg; reducing to 2mg may fall below the **therapeutic threshold** required for maintaining mental state stability.
*Switch to quetiapine and monitor mental state closely*
- **Quetiapine** is prolactin-sparing, but switching from a potent D2 antagonist like risperidone to quetiapine may carry a **higher risk of relapse** or require careful titration to maintain mental state stability.
- **Aripiprazole** is generally preferred in clinical guidelines for this specific scenario due to its unique **partial agonist mechanism** at the D2 receptor, offering a more balanced approach to managing both psychosis and hyperprolactinaemia.
Question 72: A 37-year-old man with bipolar affective disorder type I presents for preconception counselling with his partner. He has been stable on lithium carbonate 1200mg daily for 3 years with no relapses. He is concerned about the risks to the baby. His partner is not yet pregnant. What is the most appropriate advice regarding his lithium treatment in the context of preconception planning?
A. Continue lithium as paternal use has no effect on fetal development (Correct Answer)
B. Switch to sodium valproate before conception
C. Stop all mood stabilisers 3 months before conception attempt
D. Switch to lamotrigine before conception
E. Reduce lithium dose by half before conception attempt
Explanation: ***Continue lithium as paternal use has no effect on fetal development***
- Teratogenic risks associated with **lithium**, such as **Ebstein's anomaly**, are strictly related to **maternal exposure** during pregnancy and do not occur via paternal medication use.
- Since the patient has been **stable for 3 years**, maintaining the current regimen is crucial to prevent a **relapse of bipolar disorder** during the stressful transition to parenthood.
*Switch to sodium valproate before conception*
- **Sodium valproate** is highly teratogenic when used by the mother, and there is no clinical indication to switch a stable patient from lithium to valproate for **preconception planning**.
- While some recent data suggests potential risks with paternal valproate, it offers no benefit over lithium in this scenario and risks **destabilizing** the patient's mental state.
*Stop all mood stabilisers 3 months before conception attempt*
- Discontinuing a mood stabilizer in a patient with **Bipolar I Disorder** who has been stable for years carries a very high risk of **manic or depressive relapse**.
- Since **paternal lithium use** does not harm the fetus, there is no medical justification to stop treatment for the sake of the pregnancy.
*Switch to lamotrigine before conception*
- **Lamotrigine** might be a preferred option for **maternal preconception planning** to manage depressive episodes, but it is unnecessary for male patients.
- Switching from an effective treatment like lithium to lamotrigine can lead to **loss of mood control**, as lamotrigine is less effective at preventing **mania**.
*Reduce lithium dose by half before conception attempt*
- Reducing the dose of lithium below the **therapeutic window** (usually 0.6–1.0 mmol/L) significantly increases the risk of **clinical relapse**.
- **Dose-dependent toxicity** to the fetus is only a concern in maternal use; there is no evidence that a lower paternal dose reduces any nonexistent risk to the baby.
Question 73: A 28-year-old woman presents with a 3-month history of believing that her thoughts are being broadcast on television and that the government is controlling her actions through radio waves. She hears multiple voices commenting on her actions. She has become increasingly socially withdrawn. She has no previous psychiatric history, no substance misuse, and no medical comorbidities. What is the most appropriate first-line pharmacological treatment?
A. Haloperidol
B. Clozapine
C. Olanzapine (Correct Answer)
D. Chlorpromazine
E. Amisulpride and an anticholinergic
Explanation: ***Olanzapine***
- This patient presents with **first-episode schizophrenia**, characterized by positive symptoms like **thought broadcasting**, **delusions of control**, and **third-person auditory hallucinations**.
- **Second-generation (atypical) antipsychotics** like Olanzapine are the preferred first-line treatment due to a lower risk of **extrapyramidal side effects (EPSEs)** compared to older agents.
*Haloperidol*
- This is a high-potency **first-generation (typical) antipsychotic** which is effective but associated with a high incidence of **dystonia** and **parkinsonism**.
- It is generally not used as a routine first-line agent in modern practice unless specific rapid tranquilization or patient factors dictate its use.
*Clozapine*
- This drug is specifically reserved for **treatment-resistant schizophrenia**, defined as failure to respond to adequate trials of at least **two different antipsychotics**.
- It requires intensive monitoring due to the risk of life-threatening **agranulocytosis** and is never the first-line choice for a new diagnosis.
*Chlorpromazine*
- A low-potency **typical antipsychotic** that is rarely used as a first-line agent due to its significant side-effect profile, including **sedation** and **anticholinergic effects**.
- While effective for positive symptoms, it offers no clinical advantage over better-tolerated **atypical antipsychotics** in first-episode psychosis.
*Amisulpride and an anticholinergic*
- While **Amisulpride** is an effective atypical antipsychotic, the routine **prophylactic use of anticholinergics** is not recommended by clinical guidelines.
- Anticholinergics should only be added if **extrapyramidal symptoms** emerge, as they carry their own risks such as **cognitive impairment** and blurred vision.
Question 74: A 52-year-old woman with a 20-year history of bipolar affective disorder has been stable on lithium carbonate 1000mg daily for 15 years. She develops hypertension and her GP starts her on ramipril 2.5mg daily. Three weeks later, she presents feeling generally unwell. Examination shows mild tremor. Blood tests show: lithium 1.7 mmol/L (previous levels 0.7-0.9 mmol/L), creatinine 95 μmol/L (baseline 88), sodium 138 mmol/L. What is the mechanism for the change in lithium level?
A. ACE inhibitors increase lithium reabsorption in the proximal tubule
B. ACE inhibitors reduce renal blood flow causing lithium retention
C. Ramipril displaces lithium from protein binding sites
D. ACE inhibitors increase lithium reabsorption in the distal tubule due to sodium depletion (Correct Answer)
E. Ramipril inhibits hepatic metabolism of lithium
Explanation: ***ACE inhibitors increase lithium reabsorption in the distal tubule due to sodium depletion***
- **ACE inhibitors** like ramipril block the formation of **angiotensin II**, leading to decreased **aldosterone** secretion and increased **sodium excretion**.
- In response to this **sodium depletion**, the renal tubules (especially the distal nephron) enhance **sodium reabsorption**. As **lithium** is handled similarly to sodium by the kidneys, its reabsorption also increases, leading to elevated serum lithium levels and toxicity.
*ACE inhibitors increase lithium reabsorption in the proximal tubule*
- While approximately 80% of **lithium** is reabsorbed in the **proximal tubule**, the primary mechanism by which ACE inhibitors cause lithium toxicity is through changes in **sodium balance** affecting more distal parts of the nephron.
- The direct effect of **ACE inhibitors** on proximal tubule lithium reabsorption is less significant than the compensatory reabsorption driven by overall **sodium depletion** caused by the drug.
*ACE inhibitors reduce renal blood flow causing lithium retention*
- **ACE inhibitors** can cause a modest reduction in **glomerular filtration rate (GFR)** by dilating the **efferent arteriole**, which could theoretically contribute to some drug retention.
- However, the more pronounced and direct mechanism for **lithium toxicity** with ACE inhibitors is the alteration in **tubular reabsorption** due to induced **sodium depletion**, rather than a significant drop in overall renal blood flow.
*Ramipril displaces lithium from protein binding sites*
- **Lithium** is a small, inorganic ion that circulates freely in the plasma and does **not bind to plasma proteins**.
- Therefore, drug interactions involving **protein displacement**, where one drug displaces another from its binding sites, cannot occur with lithium.
*Ramipril inhibits hepatic metabolism of lithium*
- **Lithium** is unique in that it is not metabolized by the **liver** or any other organ in the body.
- It is excreted 100% unchanged by the **kidneys**; thus, any drug interaction affecting lithium levels must primarily involve changes in **renal clearance** or excretion.
Question 75: A 44-year-old man with chronic schizophrenia on clozapine 550mg daily presents to A&E with 12-hour history of fever (39.2°C), muscle rigidity, and confusion. His heart rate is 125 bpm, BP 160/95 mmHg. He is sweating profusely. Blood tests show: WCC 16 × 10⁹/L (neutrophils 14), CK 8500 U/L, creatinine 145 μmol/L (baseline 80). He last took clozapine 18 hours ago. What is the most likely diagnosis?
A. Clozapine-induced agranulocytosis with sepsis
B. Neuroleptic malignant syndrome (Correct Answer)
C. Serotonin syndrome
D. Clozapine-induced myocarditis
E. Bacterial meningitis
Explanation: ***Neuroleptic malignant syndrome***- This patient presents with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: hyperpyrexia (39.2°C), severe **muscle rigidity**, altered mental status (confusion), and **autonomic instability** (tachycardia, hypertension, diaphoresis).- Laboratory findings of significantly elevated **Creatine Kinase (CK) (8500 U/L)** and **leukocytosis (WCC 16 × 10⁹/L)** are characteristic markers of NMS, reflecting severe muscle damage and systemic stress induced by antipsychotic therapy.*Clozapine-induced agranulocytosis with sepsis*- **Agranulocytosis** is defined by a severe lack of white blood cells (specifically **neutrophils < 0.5 x 10⁹/L**), whereas this patient has an **elevated white cell count (16 x 10⁹/L)** with high neutrophils.- While sepsis causes fever and tachycardia, it does not typically cause the profound **muscle rigidity** or the massive **CK elevation** seen in this clinical picture.*Serotonin syndrome*- While it shares features of autonomic instability and altered mental status, it is often distinguished by **hyperreflexia**, **clonus**, and **myoclonus**, rather than the severe 'lead-pipe' rigidity seen in NMS.- It is usually precipitated by **serotonergic agents** and less commonly presents with such extreme CK levels reflecting severe rhabdomyolysis.*Clozapine-induced myocarditis*- This typically presents with **chest pain**, dyspnea, and signs of heart failure, usually within the **first 4-8 weeks** of starting clozapine.- While it can cause tachycardia and fever, it would not explain the **generalized muscle rigidity** or the specific laboratory finding of **rhabdomyolysis** (elevated CK).*Bacterial meningitis*- Diagnosis usually involves **neck stiffness**, headache, photophobia, and altered mental status, which are not fully aligning with the primary presentation here.- Meningitis would not account for the **marked elevation in CK** or the severe **generalized muscle rigidity** characteristic of dopamine-antagonist toxicity.
Question 76: A 35-year-old man with schizophrenia stabilised on risperidone 6mg daily for 2 years presents with reduced libido and erectile dysfunction. Examination reveals bilateral gynaecomastia. Blood tests show: prolactin 1850 mU/L (normal <400), testosterone 8.2 nmol/L (normal 10-30), TSH 2.1 mU/L, free T4 14 pmol/L. Pituitary MRI shows no structural abnormality. He is distressed and considering stopping medication. What is the most appropriate management?
A. Add cabergoline 0.5mg twice weekly
B. Switch to aripiprazole (Correct Answer)
C. Reduce risperidone to 4mg daily
D. Add testosterone replacement therapy
E. Continue risperidone and provide reassurance
Explanation: ***Switch to aripiprazole***
- **Aripiprazole** acts as a **partial D2 agonist**, which helps lower or normalize prolactin levels while maintaining antipsychotic efficacy.
- It is the most appropriate management for **antipsychotic-induced hyperprolactinaemia** when symptoms like **gynaecomastia** and **sexual dysfunction** are present.
*Add cabergoline 0.5mg twice weekly*
- **Dopamine agonists** like cabergoline are generally avoided in schizophrenia because they can potentially **exacerbate psychotic symptoms**.
- They are also associated with **cardiac valvular disease** and are for prolactinomas rather than drug-induced cases.
*Reduce risperidone to 4mg daily*
- Small dose reductions often fail to significantly reverse **hyperprolactinaemia** and increase the risk of **psychotic relapse**.
- **Risperidone** has a high affinity for D2 receptors in the **tuberoinfundibular pathway**, making prolactin elevation likely even at moderate doses.
*Add testosterone replacement therapy*
- **Testosterone therapy** does not address the primary cause (prolactin-induced suppression of the **HPA axis**) and may be ineffective while prolactin is high.
- Correcting the **hyperprolactinaemia** itself is the priority to restore endogenous hormone balance.
*Continue risperidone and provide reassurance*
- Reassurance is insufficient because the patient is **distressed** and at high risk of **treatment non-adherence**, which could lead to relapse.
- Long-term hyperprolactinaemia can lead to systemic complications such as **osteoporosis**, necessitating active clinical management.
Question 77: A 26-year-old woman with bipolar affective disorder type I presents to the emergency department with a 2-day history of confusion, tremor, and vomiting. She has been taking lithium carbonate 800mg daily. On examination, she is drowsy with a GCS of 13, temperature 37.8°C, pulse 110 bpm regular, BP 105/70 mmHg. She has coarse tremor and hyperreflexia. Blood tests show: lithium 2.8 mmol/L, sodium 148 mmol/L, potassium 4.2 mmol/L, creatinine 185 μmol/L (baseline 70), eGFR 28 ml/min/1.73m². What is the most appropriate immediate management?
A. Stop lithium and commence IV 0.9% sodium chloride rehydration
B. Stop lithium and arrange urgent haemodialysis (Correct Answer)
C. Give activated charcoal and IV fluids
D. Stop lithium, give IV fluids, and commence sodium bicarbonate
E. Reduce lithium dose to 400mg daily and recheck level in 12 hours
Explanation: ***Stop lithium and arrange urgent haemodialysis***
- **Haemodialysis** is the definitive treatment for severe lithium toxicity, indicated when serum lithium levels exceed **2.5 mmol/L** (or 4.0 mmol/L in chronic toxicity) in the presence of severe neurological symptoms like **confusion**, **altered GCS**, **coarse tremor**, and **hyperreflexia**.
- The patient also has significant **acute kidney injury** (creatinine 185 μmol/L, eGFR 28 ml/min/1.73m²), which severely impairs renal lithium clearance, making aggressive removal via haemodialysis essential to prevent permanent neurological damage.
*Stop lithium and commence IV 0.9% sodium chloride rehydration*
- While **intravenous fluids** (0.9% sodium chloride) are crucial for volume repletion and enhancing renal lithium excretion, they are insufficient as the sole treatment for severe lithium toxicity with profound **neurological compromise** and **acute kidney injury**.
- This approach is typically appropriate for milder cases of lithium toxicity or as an adjunct therapy while preparing for more definitive interventions in severe cases.
*Give activated charcoal and IV fluids*
- **Activated charcoal** is ineffective in binding lithium due to lithium's small size and ionic nature, making it unsuitable for gastrointestinal decontamination in lithium overdose.
- Management of recent ingestions typically focuses on **whole bowel irrigation** if within 1-2 hours of ingestion, or gastric lavage, not activated charcoal.
*Stop lithium, give IV fluids, and commence sodium bicarbonate*
- **Sodium bicarbonate** is used to alkalinize urine and serum in specific toxicities, such as salicylate overdose, to enhance drug excretion, but it has no established role in increasing **lithium elimination**.
- The primary fluid for rehydration in lithium toxicity is **0.9% sodium chloride** to restore euvolemia and promote renal clearance, not bicarbonate.
*Reduce lithium dose to 400mg daily and recheck level in 12 hours*
- With a critically high lithium level of **2.8 mmol/L** and severe neurological symptoms and **acute kidney injury**, continuing or merely reducing the lithium dose is **medically contraindicated** and extremely dangerous.
- Immediate and complete **discontinuation of lithium** is mandatory in any suspected or confirmed case of toxicity, followed by aggressive measures to eliminate the drug.
Question 78: A 41-year-old man with a 12-year history of paranoid schizophrenia has persistent auditory hallucinations despite trials of risperidone, olanzapine, and amisulpride at therapeutic doses for adequate durations. He is commenced on clozapine. After titration, he has been on clozapine 400mg daily for 8 weeks. His clozapine level is 380 ng/mL (therapeutic range 350-600 ng/mL) and norclozapine level is 190 ng/mL. He reports minimal improvement in hallucinations. What is the most appropriate next management step?
A. Increase clozapine to 500mg daily and recheck levels in 2 weeks (Correct Answer)
B. Add aripiprazole as augmentation
C. Switch to depot antipsychotic
D. Continue current dose for another 4 weeks before considering changes
E. Add amisulpride as augmentation
Explanation: ***Increase clozapine to 500mg daily and recheck levels in 2 weeks***- In **treatment-resistant schizophrenia**, clozapine monotherapy should be optimized to the maximum tolerated dose and **therapeutic levels** (ideally >420 ng/mL) before considering augmentation.- While the patient's level is technically within range (380 ng/mL), the **Maudsley Guidelines** recommend titration toward higher levels (up to 600 ng/mL) if clinical response remains inadequate after 8 weeks.*Add aripiprazole as augmentation*- Augmentation with **aripiprazole** is typically reserved for patients who have failed an optimized trial of clozapine monotherapy at higher serum levels.- It is often used to manage **clozapine-induced weight gain** or hyperprolactinemia rather than being the first step for therapeutic non-response.*Switch to depot antipsychotic*- **Clozapine** is the gold-standard treatment for **refractory schizophrenia**, and switching back to a depot form of a drug he has likely already failed (like risperidone) would be clinically inappropriate.- Depot medications address **non-adherence**, but the patient's current serum levels demonstrate he is already taking the oral medication reliably.*Continue current dose for another 4 weeks before considering changes*- While a full clozapine trial can take 3–6 months, continuing a **suboptimal dose** when the serum level is at the lower end of the range unnecessarily delays recovery.- Clinical guidelines advise proactive **dose adjustment** if a patient shows minimal improvement after the initial 8-week stabilization period.*Add amisulpride as augmentation*- **Amisulpride augmentation** is a recognized strategy for clozapine-resistant symptoms, but only after **clozapine monotherapy** has been fully optimized.- This patient's **clozapine/norclozapine ratio** and serum levels suggest there is still room to increase the primary medication before adding a second agent.
Question 79: A 38-year-old woman with bipolar affective disorder type I is admitted to the psychiatric ward with acute mania. She is agitated, hyperactive, and has had no sleep for 4 days. She is already taking sodium valproate 1500mg daily. Her valproate level is therapeutic at 85 mg/L. She has no known allergies. Physical examination is unremarkable except for agitation. What is the most appropriate additional pharmacological treatment?
A. Add haloperidol
B. Switch to lithium
C. Add lamotrigine
D. Increase sodium valproate to 2000mg daily
E. Add olanzapine (Correct Answer)
Explanation: ***Add olanzapine***
- In cases of **acute mania** where symptoms are not controlled by a mood stabilizer despite a **therapeutic serum level** (85 mg/L), NICE guidelines recommend adding an **antipsychotic** such as olanzapine.
- **Atypical antipsychotics** like olanzapine are preferred due to their rapid onset of action and lower risk of **extrapyramidal symptoms** compared to typical agents.
*Add haloperidol*
- While effective for mania, **haloperidol** is a first-generation antipsychotic associated with a higher incidence of **extrapyramidal side effects** and tardive dyskinesia.
- Current clinical preference favors **atypical antipsychotics** such as olanzapine, quetiapine, or risperidone as first-line add-on therapy.
*Switch to lithium*
- **Lithium** is a gold-standard mood stabilizer but has a **slow onset of action**, making it unsuitable as the sole change during a severe acute manic crisis.
- Switching drugs during an acute episode creates a dangerous **treatment gap** that could worsen the patient's agitation and insomnia.
*Add lamotrigine*
- **Lamotrigine** is primarily indicated for the prevention of **bipolar depression** and maintenance therapy; it is not effective for treating **acute mania**.
- Using this medication would fail to address the patient's immediate need for **sedation** and rapid mood stabilization.
*Increase sodium valproate to 2000mg daily*
- The patient's current **valproate level** is already within the therapeutic range (50-125 mg/L), so further dose escalation may increase **toxicity** without significantly improving the mania.
- Adding a drug from a different class (antipsychotic) provides a more robust and **synergistic clinical response** than pushing a single mood stabilizer beyond therapeutic levels.
Question 80: A 29-year-old man with paranoid schizophrenia has been taking olanzapine 20mg daily for 18 months with good symptom control. He attends for routine monitoring. His weight has increased from 78kg to 96kg (BMI from 24 to 29.5 kg/m²). Fasting blood tests show: glucose 6.8 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L. He is concerned about the weight gain. What is the most appropriate management?
A. Continue olanzapine and refer to dietitian for lifestyle modification
B. Switch to aripiprazole (Correct Answer)
C. Add metformin 500mg twice daily
D. Switch to amisulpride
E. Reduce olanzapine to 15mg daily
Explanation: ***Switch to aripiprazole***
- **Olanzapine** is well-known for its high risk of inducing **metabolic syndrome**, including significant **weight gain**, dyslipidemia, and impaired glucose tolerance.
- **Aripiprazole** has a significantly more favorable metabolic profile, being considered **metabolically neutral** or causing less weight gain, making it a suitable switch to mitigate the patient's established metabolic risks.
*Continue olanzapine and refer to dietitian for lifestyle modification*
- While lifestyle modifications are crucial, they are often insufficient to counteract the severe **metabolic side effects** caused by olanzapine, especially given the degree of **weight gain** and dyslipidemia.
- The patient already exhibits pre-diabetes and significant metabolic derangement, requiring a more proactive intervention than just lifestyle advice to prevent progression to **Type 2 Diabetes** and cardiovascular disease.
*Add metformin 500mg twice daily*
- **Metformin** is an appropriate adjunctive treatment for antipsychotic-induced metabolic issues, but the primary management when a high-risk antipsychotic like olanzapine is the cause is to consider switching to a lower-risk agent.
- Adding another medication increases **pill burden** and potential side effects, and doesn't address the underlying cause, which is the high metabolic risk of olanzapine.
*Switch to amisulpride*
- **Amisulpride** carries an intermediate risk of weight gain and metabolic side effects, and is also strongly associated with **hyperprolactinemia**, making it less ideal than aripiprazole when metabolic concerns are paramount.
- While better than olanzapine, it does not offer the same **metabolic advantage** as aripiprazole, which is preferred when significant metabolic disturbance is the reason for switching.
*Reduce olanzapine to 15mg daily*
- A small dose reduction is unlikely to significantly reverse the established **metabolic dysfunction** and severe weight gain the patient has already experienced with olanzapine.
- Reducing the dose also carries the risk of **relapse** of **paranoid schizophrenia**, as the patient's symptoms are currently well-controlled on the 20mg dose.
